Subtype
Endocrine Carcinoma
CI-CAN-00000838Explore in graph →
575 active trials16 approved drugs58 evidence items
- NCIt
- C215715
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000838Explore in graph →
Clinical trials
1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (236)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06852144 | PET-TC in Thyroid Evaluation(PEPATI-MN-2024) | enrolling by invitation | — | 418 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06748495 | Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer | active not recruiting | — | 600 | Hunan Cancer HospitalOTHER | 1 | Feb 27, 2025 |
| clinicaltrials |
| NCT06848920 | Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma | not yet recruiting | Phase 2 | 20 | Zhejiang UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03167164 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03088813 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer(RESILIENT) | completed | Phase 3 | 491 | IpsenINDUSTRY | 18 | Feb 19, 2025 | clinicaltrials |
| NCT06242119 | Clinical Application of the J-PET Scanner Prototype(JPET2Clinic) | recruiting | — | 25 | Jagiellonian UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients(CRISP) | recruiting | — | 12,400 | AIO-Studien-gGmbHOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06733740 | Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma | recruiting | — | 3,000 | Chinese PLA General HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06613009 | Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 1 | 190 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Feb 11, 2025 | clinicaltrials |
| NCT06789796 | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | not yet recruiting | Phase 3 | 636 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 11, 2025 | clinicaltrials |
| NCT06820762 | Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study | not yet recruiting | Phase 2 | 40 | The Second Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06816966 | Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC(CISART) | enrolling by invitation | Phase 2 | 35 | Fujian Medical University Union HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03532880 | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | completed | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT05623956 | Proteomics in Small Cell Lung Cancer(SCLC-OMICS) | unknown | — | 50 | Aalborg University HospitalOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin | terminated | Phase 2 | 11 | Roswell Park Cancer InstituteOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05132205 | Radiofrequency Ablation of Papillary Thyroid Microcarcinoma | completed | N/A | 10 | Johns Hopkins UniversityOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800482 | A Study of Online Follow-up in Patients With Papillary Thyroid Cancer | recruiting | N/A | 388 | West China HospitalOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT02819843 | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | completed | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06793228 | Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia | not yet recruiting | Phase 2 | 250 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06791005 | A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. | recruiting | Phase 3 | 400 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06645951 | Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma | recruiting | — | 300 | F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo SettoreOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06786312 | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06784206 | Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT03906331 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 13 | Jan 17, 2025 | clinicaltrials |
| NCT05309629 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 40 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06780826 | A Study on the Efficacy of Atezolizumab Combined with Chemotherapy | recruiting | — | 1,430 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04012606 | Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 3 | 442 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03509012 | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors(CLOVER) | completed | Phase 1 | 105 | AstraZenecaINDUSTRY | 5 | Jan 14, 2025 | clinicaltrials |
| NCT06773156 | Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer | enrolling by invitation | Phase 2 | 37 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06769971 | Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC | recruiting | Phase 2 | 80 | Sichuan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06480864 | Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer | recruiting | N/A | 38 | Yunpeng LiuOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06292988 | Predictive Factors for Medullary Thyroid Cancer Aggressiveness(MYELO) | completed | — | 500 | Aristotle University Of ThessalonikiOTHER | 24 | Jan 3, 2025 | clinicaltrials |
| NCT06725576 | Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid Carcinoma | recruiting | — | 201 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT03837977 | Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma(NET02) | completed | Phase 2 | 58 | The Christie NHS Foundation TrustOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04923776 | Liver Directed RT + Chemo-immunotherapy for ES-SCLC | terminated | Phase 2 | 2 | Brian Henick, MDOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT06749691 | Liposomal Irinotecan and Apatinib in ES-SCLC(LIAES) | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT06747832 | INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer(iNK-SCLC) | enrolling by invitation | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03043599 | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT01945762 | Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer(Caprelsa104) | completed | — | 31 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Dec 18, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05879068 | A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | active not recruiting | Phase 2 | 99 | Biotheus Inc.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 28, 2025source: clinicaltrials